In kidney transplantation, the use of minimally invasive damage biomarkers that are more
sensitive and specific than plasma creatinine will be crucial to enable early, actionable …

Cell-free DNA (cfDNA) exists in plasma and can be measured by several techniques. It is
now possible to differentiate donor-derived cfDNA (ddcfDNA) from recipient cfDNA in the …

Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive biomarker for comprehensive
monitoring of allograft injury and rejection in kidney transplantation (KTx). dd-cfDNA …

Results For diagnosing subclinical rejection, the gene expression profile demonstrated a
negative predictive value of 82%, a positive predictive value of 47%, a balanced accuracy of …

Renal transplantation is currently the most effective treatment for end-stage renal disease.
However, chronic antibody-mediated rejection (cABMR) remains a serious obstacle for the …

Risk prediction of de novo donor specific antibody (DSA) would be very important for long
term graft outcome after organ transplantation. The purpose of this study was to elucidate the …

Background: The long-term outcomes of solid organ transplantation remain suboptimal.
Therefore, appropriate biomarkers are needed in addition to immunosuppressive drugs and …

Donor specific anti-HLA antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) have
lead to substantial progress in the non-invasive monitoring of the renal allograft by being …

Antibody mediated rejection (ABMR) is the leading cause of immune-related allograft failure
following kidney transplantation. Chronic active ABMR (CABMR) typically occurs after one …

We previously established a six-gene–based blood score associated with operational
tolerance in kidney transplantation which was decreased in patients developing anti-HLA …